Tushar Bhikhubhai Patel sold $42M of AMRX
owner at Amneal Pharmaceuticals, Inc.. 5,000,000 shares at an average of $8.35, traded Mar 14, 2025, filed Mar 17, 2025.
Score components
- +12Role10% owner
- +25Trade size$41.8M at market
- 0Share of holdings soldSold 9.3% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000898432-25-000191, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 14, 2025 | SOpen-market sale Class A Common Stockindirect: By a Limited Liability Company Controlled by a Family Trust | -5,000,000 | $8.35 | $42M | 48,578,209 | Mar 17, 2025 |
Related signals
Other insiders at Amneal Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 61Notable | Amneal Pharmaceuticals, Inc. | Emily Peterson Alva director | $712k 80,000 shares | -32% | |
| 65Notable | Amneal Pharmaceuticals, Inc. | Tasos Konidaris Executive Vice President & CFO | $891k 100,000 shares | -14% | |
| 72Notable | Amneal Pharmaceuticals, Inc. | Jason B. Daly EVP, Chief Legal Officer | $792k 90,000 shares | -73% | |
| 65Notable | Amneal Pharmaceuticals, Inc. | Andrew S Boyer Executive Vice President | $1.1M 125,000 shares | -30% | |
| 31Weak | Amneal Pharmaceuticals, Inc. | Gautam Patel director | $712k 80,000 shares | -4% | |
| 15Weak | Amneal Pharmaceuticals, Inc. | Gautam Patel director | $651k 80,000 shares | -4% | |
| 13Weak | Amneal Pharmaceuticals, Inc. | Gautam Patel director | $501k 62,590 shares | -3% | |
| 6Weak | Amneal Pharmaceuticals, Inc. | Gautam Patel director | $139k 17,410 shares | -1% | |
| 26Weak | Amneal Pharmaceuticals, Inc. | John Kiely director | $143k 17,058 shares | -6% | |
| 55Moderate | Amneal Pharmaceuticals, Inc. | Deborah M. Autor director | $334k 40,000 shares | -43% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.